Modus Therapeutics AB   Report issue

For profit Phase 2
Founded: Stockholm Sweden (2011)

Organization Overview

First Clinical Trial
2011
NCT01442168
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Modus Therapeutics AB

Active Ingredients

Drugs in Phase 2 Trials (3)

atovaquone (mepron) (1 trial)

proguanil (1 trial)

sevuparin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

Malaria (Phase 2)

Malaria, Falciparum (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4